Diabetes Care, Vol 22, Issue 11 1771-1778, Copyright © 1999 by American Diabetes Association

ARTICLES

Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study

WH Herman, CM Alexander, JR Cook, SJ Boccuzzi, TA Musliner, TR Pedersen, J Kjekshus and K Pyorala
Department of Internal Medicine, University of Michigan, Ann Arbor 48109-0354, USA.

OBJECTIVE: The Scandinavian Simvastatin Survival Study showed that simvastatin treatment reduced cardiovascular events in hypercholesterolemic subjects with coronary heart disease. The clinical benefits of therapy were similar in all three subgroups: normal fasting glucose (NFG, n = 3,237), impaired fasting glucose (IFG, n = 678), and diabetes (n = 483). This analysis compared the costs of simvastatin treatment with the costs of cardiovascular disease-related hospitalizations in the three subgroups. RESEARCH DESIGN AND METHODS: The cost of simvastatin treatment was defined as the average retail price and the cost of drug safety monitoring and adverse experiences. The costs of cardiovascular disease-related hospitalizations were determined by actual rates of hospitalization and 1995 MEDSTAT diagnosis-related group costs. RESULTS: Within trial, simvastatin treatment cost approximately $6,000 per patient. Simvastatin treatment reduced cardiovascular disease-related hospitalizations by 23% in NFG (P = 0.001), 30% in IFG (P = 0.015), and 40% in diabetic subjects (P = 0.007) within trial (median follow-up of 5.4 years). Average length of stay was reduced by 2.4 days in diabetic subjects (P = 0.021). Total cardiovascular disease-related hospital days were reduced by 28% (P < 0.001) in NFG, 38% (P = 0.005) in IFG, and 55% (P < 0.001) in diabetic subjects. For NFG subjects, simvastatin reduced the average cost of cardiovascular disease-related hospitalizations by $3,585, which offset 60% of the cost of simvastatin therapy. For IFG subjects, average cardiovascular disease-related hospitalization costs were reduced by $4,478, which offset 74% of the drug cost. For diabetic subjects, there was a net cost savings of $1,801 per subject within trial. CONCLUSIONS: Simvastatin significantly reduced cardiovascular disease-related hospitalizations and total hospital days for all three groups and significantly reduced length of stay for the diabetic group in addition to providing significant clinical benefits. The benefits were greatest in the diabetic group, with estimated cost savings within trial from simvastatin treatment.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				T. P. Gilmer, P. J. O'Connor, W. A. Rush, A. L. Crain, R. R. Whitebird, A. M. Hanson, and L. I. Solberg Predictors of Health Care Costs in Adults With Diabetes Diabetes Care, January 1, 2005; 28(1): 59 - 64. [Abstract] [Full Text] [PDF]

				M. Trovati and F. Cavalot Optimization of Hypolipidemic and Antiplatelet Treatment in the Diabetic Patient with Renal Disease J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S12 - 20. [Abstract] [Full Text]

				V. G. Athyros, A. A. Papageorgiou, A. N. Symeonidis, T. P. Didangelos, A. N. Pehlivanidis, V. I. Bouloukos, and D. P. Mikhailidis Early Benefit from Structured Care with Atorvastatin in Patients with Coronary Heart Disease and Diabetes Mellitus: A Subgroup Analysis of the GREek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study Angiology, November 1, 2003; 54(6): 679 - 690. [Abstract] [PDF]

				S. Ma, J. Cutter, C. E. Tan, S. K. Chew, and E. S. Tai Associations of Diabetes Mellitus and Ethnicity with Mortality in a Multiethnic Asian Population: Data from the 1992 Singapore National Health Survey Am. J. Epidemiol., September 15, 2003; 158(6): 543 - 552. [Abstract] [Full Text] [PDF]

				M. Brandle, M. B. Davidson, D. L. Schriger, B. Lorber, and W. H. Herman Cost Effectiveness of Statin Therapy for the Primary Prevention of Major Coronary Events in Individuals With Type 2 Diabetes Diabetes Care, June 1, 2003; 26(6): 1796 - 1801. [Abstract] [Full Text] [PDF]

				R. S. Weinstock Treating Type 2 Diabetes Mellitus: A Growing Epidemic Mayo Clin. Proc., April 1, 2003; 78(4): 411 - 413. [PDF]

				Management of Dyslipidemia in Adults With Diabetes Diabetes Care, January 1, 2003; 26(90001): s83 - 86. [Full Text] [PDF]